Active — Not RecruitingNot Applicable

Simplifying Treatment and Monitoring for HIV (STREAM HIV)

South Africa539 participantsStarted 2021-02-04

Plain-language summary

This study seeks to determine the clinical efficacy and cost effectiveness of implementing an integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence testing and POC viral load (VL) monitoring in improving ART adherence, maintaining durable VL suppression, and improving retention in care among HIV-positive individuals initiating first-line tenofovir disoproxil fumarate (TDF)-based ART in South Africa.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HIV-positive * ≥16 years old * Initiating a TDF-based, first-line ART regimen * Do not self-report being on an ART regimen in the prior month * Willing/able to provide written informed consent Exclusion Criteria: * Does not plan to continue receiving HIV care at the CDC Clinic * Per the decision or opinion of the PI (for example, a clinically significant acute or chronic medical condition or circumstances that would make the patient unsuitable for participation or jeopardize the safety or rights of the participant

What they're measuring

Number of Participants With Viral Load Suppression (<200 Copies/ml) and Retained in Care at 72 Weeks

Timeframe: 72 weeks after ART initiation

Tenofovir Diphosphate Concentration Level >=700 Fmol/Punch in Dried Blood Spots

Timeframe: 72 weeks after ART initiation

Trial details

NCT IDNCT04341779

SponsorUniversity of Washington

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-30

Results submitted2025-09-30

View on ClinicalTrials.gov More HIV/AIDS trials